JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Herpes zoster and dementia : more evidences for a causal link712
Gene and genetic therapies in Alzheimer’s disease and other dementias190
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort154
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats130
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France127
Lecanemab over a two-year duration: Key insights from a regional specialty medical center101
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.100
Long-term fasting insulin variability and cognitive function: Insights from the CARDIA study98
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice86
Prevention of dementia using mobile phone applications (PRODEMOS) – a health-economic cost-utility analysis in people aged 55–75 years with low socio-economic status83
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data74
Structural social factors modify the association between Alzheimer’s pathology and cognitive function70
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use64
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease62
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings51
Sleep complaints and genetic risk of Alzheimer’s disease in older women: associations with memory and tau deposition51
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation51
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau21748
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease47
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status43
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations43
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment41
Introduction to the Special Issue on the A4 Study41
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese39
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review39
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test38
Content37
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population36
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 635
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care35
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias34
Informal care for people with dementia in Europe34
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system32
Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer’s disease32
0.37511515617371